Cargando…
The Feasibility of Percutaneous Dilatational Tracheostomy in Immunosuppressed ICU Patients with or without Thrombocytopenia
BACKGROUND: Percutaneous dilatational tracheostomy (PDT) has become the preferred method in several intensive care units (ICUs), but data on PDT performed in immunosuppressed and thrombocytopenic patients are scarce. This study aimed to analyze the feasibility of PDT in immunosuppressed and thromboc...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9134848/ https://www.ncbi.nlm.nih.gov/pubmed/35646396 http://dx.doi.org/10.1155/2022/5356413 |
_version_ | 1784713840942907392 |
---|---|
author | Angelberger, Marianne Barnikel, Michaela Fraccaroli, Alessia Tischer, Johanna Antón, Sofía Pawlikowski, Alexandra op den Winkel, Mark Stemmler, Hans Joachim Stecher, Stephanie-Susanne |
author_facet | Angelberger, Marianne Barnikel, Michaela Fraccaroli, Alessia Tischer, Johanna Antón, Sofía Pawlikowski, Alexandra op den Winkel, Mark Stemmler, Hans Joachim Stecher, Stephanie-Susanne |
author_sort | Angelberger, Marianne |
collection | PubMed |
description | BACKGROUND: Percutaneous dilatational tracheostomy (PDT) has become the preferred method in several intensive care units (ICUs), but data on PDT performed in immunosuppressed and thrombocytopenic patients are scarce. This study aimed to analyze the feasibility of PDT in immunosuppressed and thrombocytopenic patients compared to conventional open surgical tracheostomy (OST). METHODS: We retrospectively analyzed the charts of patients who underwent PDT or OST between May 2017 and November 2020. Our outcomes were stoma site infections and bleeding complications. RESULTS: 63 patients underwent PDT, and 21 patients underwent OST. Distribution of gender ratio, age, SAPS II, time of ventilation before tracheostomy, and preexisting hematooncological diseases was comparable between the two groups. After allogeneic stem cell transplantation (alloSCT), patients were more likely to undergo PDT than OST (p=0.033). The PDT cohort suffered from mucositis more frequently (p=0.043). There were no significant differences in leucocyte or platelet count on the tracheostomy day. Patients with coagulation disorders and patients under immunosuppression were distributed equally among both groups. Stoma site infection was documented in five cases in PDT and eight cases in the OST group. Moderate infections were remarkably increased in the OST group. Smears were positive in six cases in the PDT group; none of these patients had local infection signs. In the OST group, smears were positive in four cases; all had signs of a stroma site infection. Postprocedural bleedings occurred in eight cases (9.5%) and were observed significantly more often in the OST group (p=0.001), leading to emergency surgery in one case of the OST group. CONCLUSION: PDT is a feasible and safe procedure in a predominantly immunosuppressed and thrombocytopenic patient cohort without an increased risk for stoma site infections or bleeding complications. |
format | Online Article Text |
id | pubmed-9134848 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Hindawi |
record_format | MEDLINE/PubMed |
spelling | pubmed-91348482022-05-27 The Feasibility of Percutaneous Dilatational Tracheostomy in Immunosuppressed ICU Patients with or without Thrombocytopenia Angelberger, Marianne Barnikel, Michaela Fraccaroli, Alessia Tischer, Johanna Antón, Sofía Pawlikowski, Alexandra op den Winkel, Mark Stemmler, Hans Joachim Stecher, Stephanie-Susanne Crit Care Res Pract Research Article BACKGROUND: Percutaneous dilatational tracheostomy (PDT) has become the preferred method in several intensive care units (ICUs), but data on PDT performed in immunosuppressed and thrombocytopenic patients are scarce. This study aimed to analyze the feasibility of PDT in immunosuppressed and thrombocytopenic patients compared to conventional open surgical tracheostomy (OST). METHODS: We retrospectively analyzed the charts of patients who underwent PDT or OST between May 2017 and November 2020. Our outcomes were stoma site infections and bleeding complications. RESULTS: 63 patients underwent PDT, and 21 patients underwent OST. Distribution of gender ratio, age, SAPS II, time of ventilation before tracheostomy, and preexisting hematooncological diseases was comparable between the two groups. After allogeneic stem cell transplantation (alloSCT), patients were more likely to undergo PDT than OST (p=0.033). The PDT cohort suffered from mucositis more frequently (p=0.043). There were no significant differences in leucocyte or platelet count on the tracheostomy day. Patients with coagulation disorders and patients under immunosuppression were distributed equally among both groups. Stoma site infection was documented in five cases in PDT and eight cases in the OST group. Moderate infections were remarkably increased in the OST group. Smears were positive in six cases in the PDT group; none of these patients had local infection signs. In the OST group, smears were positive in four cases; all had signs of a stroma site infection. Postprocedural bleedings occurred in eight cases (9.5%) and were observed significantly more often in the OST group (p=0.001), leading to emergency surgery in one case of the OST group. CONCLUSION: PDT is a feasible and safe procedure in a predominantly immunosuppressed and thrombocytopenic patient cohort without an increased risk for stoma site infections or bleeding complications. Hindawi 2022-05-26 /pmc/articles/PMC9134848/ /pubmed/35646396 http://dx.doi.org/10.1155/2022/5356413 Text en Copyright © 2022 Marianne Angelberger et al. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Article Angelberger, Marianne Barnikel, Michaela Fraccaroli, Alessia Tischer, Johanna Antón, Sofía Pawlikowski, Alexandra op den Winkel, Mark Stemmler, Hans Joachim Stecher, Stephanie-Susanne The Feasibility of Percutaneous Dilatational Tracheostomy in Immunosuppressed ICU Patients with or without Thrombocytopenia |
title | The Feasibility of Percutaneous Dilatational Tracheostomy in Immunosuppressed ICU Patients with or without Thrombocytopenia |
title_full | The Feasibility of Percutaneous Dilatational Tracheostomy in Immunosuppressed ICU Patients with or without Thrombocytopenia |
title_fullStr | The Feasibility of Percutaneous Dilatational Tracheostomy in Immunosuppressed ICU Patients with or without Thrombocytopenia |
title_full_unstemmed | The Feasibility of Percutaneous Dilatational Tracheostomy in Immunosuppressed ICU Patients with or without Thrombocytopenia |
title_short | The Feasibility of Percutaneous Dilatational Tracheostomy in Immunosuppressed ICU Patients with or without Thrombocytopenia |
title_sort | feasibility of percutaneous dilatational tracheostomy in immunosuppressed icu patients with or without thrombocytopenia |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9134848/ https://www.ncbi.nlm.nih.gov/pubmed/35646396 http://dx.doi.org/10.1155/2022/5356413 |
work_keys_str_mv | AT angelbergermarianne thefeasibilityofpercutaneousdilatationaltracheostomyinimmunosuppressedicupatientswithorwithoutthrombocytopenia AT barnikelmichaela thefeasibilityofpercutaneousdilatationaltracheostomyinimmunosuppressedicupatientswithorwithoutthrombocytopenia AT fraccarolialessia thefeasibilityofpercutaneousdilatationaltracheostomyinimmunosuppressedicupatientswithorwithoutthrombocytopenia AT tischerjohanna thefeasibilityofpercutaneousdilatationaltracheostomyinimmunosuppressedicupatientswithorwithoutthrombocytopenia AT antonsofia thefeasibilityofpercutaneousdilatationaltracheostomyinimmunosuppressedicupatientswithorwithoutthrombocytopenia AT pawlikowskialexandra thefeasibilityofpercutaneousdilatationaltracheostomyinimmunosuppressedicupatientswithorwithoutthrombocytopenia AT opdenwinkelmark thefeasibilityofpercutaneousdilatationaltracheostomyinimmunosuppressedicupatientswithorwithoutthrombocytopenia AT stemmlerhansjoachim thefeasibilityofpercutaneousdilatationaltracheostomyinimmunosuppressedicupatientswithorwithoutthrombocytopenia AT stecherstephaniesusanne thefeasibilityofpercutaneousdilatationaltracheostomyinimmunosuppressedicupatientswithorwithoutthrombocytopenia AT angelbergermarianne feasibilityofpercutaneousdilatationaltracheostomyinimmunosuppressedicupatientswithorwithoutthrombocytopenia AT barnikelmichaela feasibilityofpercutaneousdilatationaltracheostomyinimmunosuppressedicupatientswithorwithoutthrombocytopenia AT fraccarolialessia feasibilityofpercutaneousdilatationaltracheostomyinimmunosuppressedicupatientswithorwithoutthrombocytopenia AT tischerjohanna feasibilityofpercutaneousdilatationaltracheostomyinimmunosuppressedicupatientswithorwithoutthrombocytopenia AT antonsofia feasibilityofpercutaneousdilatationaltracheostomyinimmunosuppressedicupatientswithorwithoutthrombocytopenia AT pawlikowskialexandra feasibilityofpercutaneousdilatationaltracheostomyinimmunosuppressedicupatientswithorwithoutthrombocytopenia AT opdenwinkelmark feasibilityofpercutaneousdilatationaltracheostomyinimmunosuppressedicupatientswithorwithoutthrombocytopenia AT stemmlerhansjoachim feasibilityofpercutaneousdilatationaltracheostomyinimmunosuppressedicupatientswithorwithoutthrombocytopenia AT stecherstephaniesusanne feasibilityofpercutaneousdilatationaltracheostomyinimmunosuppressedicupatientswithorwithoutthrombocytopenia |